MicroRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF)

International Journal of Biochemistry and Molecular Biology

Volumn 3, Issue 4, 2012, Pages 365-373

  Alexandrov, Peter N ^a   Dua, Prerna ^b   Hill, James M ^c,d   Bhattacharjee, Surjyadipta ^c   Zhao, Yuhai ^c   Lukiw, Walter J ^a,c,d  

^a INSTITUTE OF BIOMEDICAL CHEMISTRY   (Russian Federation)

^b LOUISIANA STATE UNIVERSITY   (United States)

^c LOUISIANA STATE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Alzheimer's disease (AD); CAPE (caffeic acid phenethyl ester); CAY10512 (1 fluoro 2 2 (4 methoxyphenyl) ethenyl benzene); Inflammatory signaling; Micro RNA; NF kB

Indexed keywords

AMYLOID BETA PROTEIN[1-42]; CAFFEIC ACID PHENETHYL ESTER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICRORNA; MICRORNA 125B; MICRORNA 146A; MICRORNA 155; MICRORNA 9;

AGED; ALZHEIMER DISEASE; ARTICLE; CADAVER; CEREBROSPINAL FLUID; COCULTURE; CONTROLLED STUDY; DOWN REGULATION; EXTRACELLULAR FLUID; GLIA CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; NEOCORTEX; NERVE CELL; NERVE DEGENERATION; NORTHERN BLOTTING; UPREGULATION;

EID: 84871695724     PISSN: None     EISSN: 21524114     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Alzheimer Association: 2012 Alzheimer's Disease Facts and Figures statistical resource. Available from: http://www.alz.org/downloads/Facts_Figures_2012.pdf.
2. Lukiw WJ. Amyloid beta (Aβ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD). Expert Opin Emerg Drugs 2012; Mar 23. [Epub ahead of print].
3. Cui JG, Hill JM, Zhao Y, Lukiw WJ. Expression of inflammatory genes in the primary visual cortex of late-stage Alzheimer's disease. Neuroreport 2007; 18: 115-119.
4. Bancher C, Braak H, Fischer P, Jellinger KA. Neuropathological staging of Alzheimer lesions and intellectual status in Alzheimer's and Parkinson's disease patients. Neurosci Lett 1993; 162: 179-182.
5. Thompson PM, Hayashi KM, De Zubicaray GI, Janke AL, Rose SE, Semple J, Hong MS, Herman DH, Gravano D, Doddrell DM, Toga AW. Mapping hippocampal and ventricular change in Alzheimer disease. Neuroimage 2004; 22: 1754-1766.
6. Lee SJ, Lim HS, Masliah E, Lee HJ. Protein aggregate spreading in neurodegenerative diseases: problems and perspectives. Neurosci Res 2011; 70: 339-348.
7. Jucker M, Walker LC. Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann Neurol 2011; 70: 532-540.
8. McLachlan DRC, Lukiw WJ, Kruck TP. New evidence for an active role of aluminum in Alzheimer's disease. Can J Neurol Sci 1989; 16: 490-497.
9. Lukiw WJ. Evidence supporting a biological role for aluminum in chromatin compaction and epigenetics. J Inorg Biochem 2010; 104: 1010-1012.
10. Girouard H, Iadecola C. Neurovascular coupling in the normal brain and in hypertension, stroke, and Alzheimer disease. J Appl Physiol 2006; 100: 328-335.
11. Kruck TP, Cui JG, Percy ME, Lukiw WJ. Molecular shuttle chelation: The use of ascorbate, desferrioxamine and Feralex-G in combination. Cellular and Molecular Neurobiology 2004; 24: 443-459.
12. Cui JG, Zhao Y, Sethi P, Li YY, Mahta A, Culicchia F, Lukiw WJ. Micro-RNA-128 (miRNA-128) down-regulation in glioblastoma targets ARP5 (ANGPTL6), Bmi-1 and E2F-3a, key regulators of brain cell proliferation. J Neurooncol 2010; 98: 297-304.
13. Lukiw WJ. NF-kB-regulated micro RNAs (miR-NAs) in primary human brain and retinal cells, Experimental Neurology 2011; Nov 23 [Epub ahead of print].
14. Shoji M. Molecular approaches to the treatment, prophylaxis, and diagnosis of Alzheimer's disease: clinical molecular and genetic studies on Alzheimer's disease. J Pharmacol Sci 2012; 118: 345-349.
15. Molinuevo JL, Sánchez-Valle R, Lladó A, Fortea J, Bartrés-Faz D, Rami L. Identifying earlier Alzheimer's disease: insights from the preclinical and prodromal phases. Neurodegener Dis 2012; 10: 158-160.
16. Humpel C. Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol 2011; 29: 26-32.
17. Papaliagkas VT, Tsolaki M, Anogianakis G. Cerebrospinal fluid proteins in the diagnosis of Alzheimer's disease. Recent Pat CNS Drug Discov 2010; 5: 172-178.
18. Blennow K, Hampel H, Weiner M, Zetterberg H. Cerebrospinal fluid and plasma biomarkers in Alzheimer disease. Nat Rev Neurol 2010; 6: 131-144.
19. Zhao Y, Cui JG, Lukiw WJ. Natural secretory products of human neural and microvessel endothelial cells: Implications in pathogenic "spreading" and Alzheimer's disease. Mol Neurobiol 2006; 34: 181-192.
20. Lukiw WJ, Surjyadipta B, Dua P, Alexandrov PN. Common micro RNAs (miRNAs) target complement factor H (CFH) regulation in Alzheimer's disease (AD) and in age-related macular degeneration (AMD). Int J Biochem Mol Biol 2012; 3: 105-116.
21. Lukiw WJ, Zhao Y, Cui JG. An NF-kB-sensitive micro RNA-146a-mediated inflammatory circuit in Alzheimer disease and in stressed human brain cells. J Biol Chem 2008; 283: 31315-31322.
22. Cui JG, Li YY, Zhao Y, Bhattacharjee S, Lukiw WJ. Differential regulation of interleukin-1 receptor-associated kinase-1 (IRAK-1) and IRAK-2 by microRNA-146a and NF-kB in stressed human astroglial cells. J Biol Chem 2010; 285: 38951-38960.
23. Hill JM, Lukiw WJ, Gebhardt BM, Higaki S, Loutsch JM, Myles ME, Thompson HW, Kaufman HE. Gene expression analyzed by microarrays in HSV-1 latent mouse trigeminal ganglion following heat stress. Virus Genes 2001; 23: 273-280.
24. Higaki S, Gebhardt BM, Lukiw WJ, Thompson HW, Hill JM. Effect of immunosuppression on gene expression in the HSV-1 latently infected mouse trigeminal ganglion. Investigative Ophthalmology and Visual Science 2002; 43: 1862-1869.
25. Lukiw WJ, Bazan NG. Survival signaling in Alzheimer's disease. Biochemical Society Transactions 2006; 34: 1277-1282.
26. Pall GS, Hamilton AJ. Improved northern blot method for enhanced detection of small RNA. Nat Protoc 2008; 3: 1077-1084.
27. Pall GS, Codony-Servat C, Byrne J, Ritchie L, Hamilton A. Carbodiimide-mediated cross-linking of RNA to nylon membranes improves the detection of siRNA, miRNA and piRNA by northern blot. Nucleic Acids Res 2007; 35: e60.
28. Kim SW, Li Z, Moore PS, Monaghan AP, Chang Y, Nichols M, John B. A sensitive non-radioactive northern blot method to detect small RNAs. Nucleic Acids Res 2010; 38: e98.
29. Lukiw WJ, Alexandrov PN, Zhao Y, Hill JM, Bhattacharjee S. Spreading of Alzheimer's disease inflammatory signaling through soluble micro-RNA. Neuroreport 2012; 23: 621-626.
30. Lukiw WJ, Cui JG, Marcheselli VL, Bodker M, Botkjaer A, Gotlinger K, Serhan CN, Bazan NG. A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease. J Clin Invest 2005; 115: 2774-2783.
31. Zhao Y, Calon F, Julien C, Winkler JW, Petasis NA, Lukiw WJ, Bazan NG. Docosahexaenoic acid-derived neuroprotectin D1 (NPD1) induces neuronal survival via secretase- and PPARγmediatedmechanisms in Alzheimer's disease models. PLoS One 2011; 6: e15816.
32. Shaftel SS, Griffin WS, O'Banion MK. The role of interleukin-1 in neuroinflammation and Alzheimer disease: an evolving perspective. J Neuroinflammation 2008; 5: 7-11.
33. Colangelo V, Schurr J, Ball MJ, Pelaez RP, Bazan NG, Lukiw WJ. Gene expression profiling of 12633 genes in Alzheimer hippocampal CA1: transcription and neurotrophic factor downregulation and up-regulation of apoptotic and pro-inflammatory signaling. J Neurosci Res 2002; 70: 462-473.
34. Sardi F, Fassina L, Venturini L, Inguscio M, Guerriero F, Rolfo E, Ricevuti G. Alzheimer's disease, autoimmunity and inflammation. The good, the bad and the ugly. Autoimmun Rev 2011; 11: 149-153.
35. Lukiw WJ, Bazan NG. Strong NF-kB-DNA binding parallels cyclooxygenase-2 gene transcription in aging and in sporadic Alzheimer's disease superior temporal lobe neocortex. J Neurosci Res 1998; 53: 583-592.
36. Hansson O, Zetterberg H, Buchhave P, Londos E, Blennow K, Minthon L. Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006; 5: 228-234.
37. Zetterberg H, Wahlund LO, Blennow K. Cerebrospinal fluid markers for prediction of Alzheimer's disease. Neurosci Lett 2003; 352: 67-69.
38. Guo H, Ingolia NT, Weissman JS, Bartel DP. Mammalian miRNAs act to decrease target mRNA levels. Nature 2010; 466: 835-840.
39. Lukiw WJ. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport 2007; 18: 297-300.
40. Lukiw WJ, Pogue AI. Induction of specific micro RNA (miRNA) species by ROS-generating metal sulfates in primary human brain cells. J Inorg Biochem 2007; 101: 1265-1269.
41. Eisele YS, Bolmont T, Heikenwalder M, Langer F, Jacobson LH, Yan ZX, Roth K, Aguzzi A, Staufenbiel M, Walker LC, Jucker M. Induction of cerebral beta-amyloidosis: intracerebral versus systemic Abeta inoculation. Proc Natl Acad Sci U S A 2009; 106: 12926-12931.
42. Eisele YS, Obermüller U, Heilbronner G, Baumann F, Kaeser SA, Wolburg H, Walker LC, Staufenbiel M, Heikenwalder M, Jucker M. Peripherally applied Abeta-containing inoculates induce cerebral beta-amyloidosis. Science 2010; 330: 980-982.
43. Li YY, Cui JG, Dua P, Pogue AI, Bhattacharjee S, Lukiw WJ. Differential expression of miR-NA-146a-regulated inflammatory genes in human primary neural, astroglial and microglial cells. Neurosci Lett 2011; 499: 109-13.
44. Delay C, Mandemakers W, Hébert SS. MicroR-NAs in Alzheimer's disease. Neurobiol Dis 2012; 46: 285-290.
45. Lukiw WJ. Evolution and complexity of micro RNA in the human brain. Front Genet 2012; 3: 166-168.